Prosigna identified a large high-clinical-risk subgroup with minimal chemotherapy benefit, estimated to avert at most two recurrences per 100 patients treated. Enrollment broadened prior assay use by ...
Dr. Paolo Tarantino discusses the importance of strategic sequencing and drug-specific prophylaxis to optimize ADC therapy in breast cancer. The rise of antibody-drug conjugates (ADCs) has transformed ...
Median overall survival improved by 4.1 months with relacorilant plus nab-paclitaxel versus nab-paclitaxel alone (16.0 vs 11.9 months) at 24.8 months’ median follow-up. Prespecified subgroup analyses ...
Dr. Maurie Markman, joins The Moonlight Shift to discuss precision medicine's real-world limits, oncology's cost crisis, ...
OptiTROP-Lung05 randomized 413 untreated, PD-L1 ≥1% advanced NSCLC patients without EGFR/ALK alterations to sac-TMT+pembrolizumab versus pembrolizumab; primary endpoint was PFS. Median PFS was not ...
Progressive disease triggered insomnia and anticipatory grief, highlighting common symptom burden and emotional distress ...
After losing his mother to colorectal cancer in 2009, Michael Sapienza turned unimaginable grief into action. Today, as CEO ...
A patient shares motivation after CAR T/TIL therapy as experts reveal caregiver tips for recovery, safety, and avoiding burnout. Timing matters when considering tumor-infiltrating lymphocyte (TIL) ...
Here are some of the key gynecologic cancer presentations to watch at ASCO 2026.
First-in-human pancreatic cancer trial at WVU tests an implant that delivers chemotherapy directly into tumors using low-voltage electric pulses. The WVU Cancer Institute is helping lead a global ...
A cancer survivor’s wife created a life transition binder during his treatment to organize medical, financial and household information to access details in emergencies. After being diagnosed with ...
Disease-free survival improved with durvalumab plus BCG induction/maintenance versus BCG alone, reducing recurrence/progression/death risk (HR 0.68; p=0.0154) with median DFS not reached. Eligibility ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results